IPO Year: 2022
Exchange: NASDAQ
10-Q - Tharimmune, Inc. (0001861657) (Filer)
424B3 - Tharimmune, Inc. (0001861657) (Filer)
EFFECT - Tharimmune, Inc. (0001861657) (Filer)
S-3 - Tharimmune, Inc. (0001861657) (Filer)
D - Tharimmune, Inc. (0001861657) (Filer)
8-K - Tharimmune, Inc. (0001861657) (Filer)
S-8 - Tharimmune, Inc. (0001861657) (Filer)
8-K - Tharimmune, Inc. (0001861657) (Filer)
8-K - Tharimmune, Inc. (0001861657) (Filer)
424B5 - Tharimmune, Inc. (0001861657) (Filer)
BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).Prof. Jones has earned an international reputation for his work in autoimmune liver disease. He leads the UK-PBC research consortium (MRC Stratified Medicine), which has the world's largest cohort of fully phenotyped primary biliary cholangitis/cirrhosis (PBC) patients. His areas of expertise include stratified the
BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team."Tharimmune is pleased to have David join in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his wide-ranging accomplishments and business insight will meaningfully strengthen our organization. In particular, we expect that his understanding of publicly traded company operations coupled with his leadership skills will provide stra
BRIDGEWATER, NJ / ACCESSWIRE / July 10, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of Jules Haimovitz as a Strategic Advisor to the Company's executive management team."We are pleased to have Jules join Tharimmune in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his extensive success in the biotechnology industry, robust professional network and strategic acumen will significantly bolster our clinical and preclinical programs. Particularly noteworthy is our recent positive FDA feedback on the
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. Venus Concept (NASDAQ:VERO) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. Tharimmune (NASDAQ:THAR) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. Kineta (NASDAQ:KA) shares moved upwards by
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program. Skye Bioscience shares tumbled 18.9% to $8.87 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) shares jumped 123% to $4.3001 following the completion of the company’s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week. KWESST Micro Systems Inc. (NASDAQ:KWE) gained 79.8% to $0.7082 after the company was aw
Gainers Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. Renovaro (NASDAQ:RENB) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. Nanoviricides (AMEX:NNVC) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. Semler Scientific (NASDAQ:SMLR) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. TransCode Therapeutics (N
Tharimmune Inc (NASDAQ:THAR) shares are trading lower by 30% to $3.60 during Monday’s session. The company late Friday announced it had entered into an “at the market” offering agreement with Rodman & Renshaw LLC for the sale of up to $1.65 million worth of its common stock through the sales agent. The stock is listed on Nasdaq under the symbol “THAR,” with a last reported price of $5.17 per share on June 5, 2024. The sales agent will sell shares using commercially reasonable efforts and is entitled to a 3% commission on the gross proceeds. They may also purchase shares as a principal under separately negotiated terms. As a smaller reporting and emerging growth company, the company ben
- Form 8-K
BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).Prof. Jones has earned an international reputation for his work in autoimmune liver disease. He leads the UK-PBC research consortium (MRC Stratified Medicine), which has the world's largest cohort of fully phenotyped primary biliary cholangitis/cirrhosis (PBC) patients. His areas of expertise include stratified the
BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team."Tharimmune is pleased to have David join in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his wide-ranging accomplishments and business insight will meaningfully strengthen our organization. In particular, we expect that his understanding of publicly traded company operations coupled with his leadership skills will provide stra
BRIDGEWATER, NJ / ACCESSWIRE / July 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announces the launch of its new website at www.tharimmune.com. This redesigned online platform provides patients, healthcare professionals and stakeholders with comprehensive information about Tharimmune's cutting-edge research, ongoing clinical trials and corporate developments."Our new website represents a valuable resource in our commitment to engage with the broader medical community and our investors," said Randy Milby, CEO of Tharimmune. "We believe this platfo
BRIDGEWATER, NJ / ACCESSWIRE / July 10, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of Jules Haimovitz as a Strategic Advisor to the Company's executive management team."We are pleased to have Jules join Tharimmune in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his extensive success in the biotechnology industry, robust professional network and strategic acumen will significantly bolster our clinical and preclinical programs. Particularly noteworthy is our recent positive FDA feedback on the
BRIDGEWATER, NJ / ACCESSWIRE / June 20, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, developing lead candidate, TH104 for chronic pruritus in primary biliary cholangitis announced today that it has entered into a securities purchase agreement for the purchase and sale of an aggregate of 659,545 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 329,771 shares of common stock at a purchase price of $3.16 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying w
FDA Provides Positive Feedback to Company Regarding TH104 Phase 2 ProgramCompany Incorporating FDA Feedback into Phase 2 ProtocolCompany Believes it is On-track to Initiate Phase 2 Trial BRIDGEWATER, NJ / ACCESSWIRE / June 17, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, reports positive Type C meeting feedback from the U.S. Food and Drug Administration (FDA) for its Phase 2 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene for moderate-to-severe pruritus or "uncontrolled itchin
Pharmacokinetic profile of oral transmucosal delivery of TH104 was comparable to intravenous delivery of reference drugPositive safety/tolerability achieved with TH104 reporting a mild side-effect profilePlanning for Phase 2 trial for moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) is ongoing and on track to initiate in 2024 BRIDGEWATER, NJ / ACCESSWIRE / June 10, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, reports positive results from its Phase 1 clinical trial with TH104, a proprietary transmucosal buccal film embedded
BRIDGEWATER, NJ / ACCESSWIRE / May 29, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego.The Company will be presenting at the convention and will hold 1x1 meetings with investors and industry leaders.Event:2024 BIO International ConventionDate:Monday, June 3, 2024Time:1:45 p.m. Pacific TimeLocation:Company Presentation Theater 3To schedule a meeting with the Company's management at the convention, please submit a meeting request
BRIDGEWATER, NJ / ACCESSWIRE / May 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it will effect a 1-for-15 reverse stock split of its issued and outstanding shares of common stock after the close of trading on The Nasdaq Capital Market ("Nasdaq") on May 24, 2024. Tharimmune's common stock will trade on a post-split basis when the market opens on May 28, 2024 under the existing trading symbol "THAR" and the new CUSIP number 432705309. The reverse stock split was approved by Tharimmune stockholders at the Annual Meeting of Sto
BRIDGEWATER, NJ / ACCESSWIRE / April 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced that management will be participating in two investor conferences in May.Randy Milby, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: VEGAS 2024 being held at the Paris Hotel & Casino in Las Vegas, Nevada, and will hold 1x1 meetings with investors. Investors interested in meeting with Tharimmune can register for the conference here.Event:Planet MicroCap Showcase: VEGAS 2024Date:Wednesday, May 1, 2024Time:3:30 p.m. Pacific TimeWe